Sana Biotechnology, a company that develops platforms to replace or repair cells in our bodies, wrapped an upsized IPO at $588 million.
Morgan Stanley, Goldman Sachs Group, JPMorgan and BofA Securities were the bookrunners for the deal.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.04 |
|---|---|
| 52-week range | $2.75 - $12.00 |
| 50-day moving average | $5.54 |
| 200-day moving average | $6.67 |
| Wall St. target price | $13.60 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.04 from 2024-09-06
| 1 week (2024-08-30) | -16.69% |
|---|---|
| 1 month (2024-08-07) | 6.78% |
| 3 months (2024-06-07) | -27.79% |
| 6 months (2024-03-07) | -47.39% |
| 1 year (2023-09-07) | -9.03% |
|---|---|
| 2 years (2022-09-07) | -26.53% |
| 3 years (2021-09-07) | 23.69 |
| 5 years (2019-09-03) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -27.91% |
| Return on equity TTM | -70.51% |
| Profit margin | 0% |
| Book value | $1.53 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting Sana Biotechnology Inc to pay a dividend over the next 12 months.
Over the last 12 months, Sana Biotechnology Inc's shares have ranged in value from as little as $2.745 up to $12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sana Biotechnology Inc's is 1.451. This would suggest that Sana Biotechnology Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Sana Biotechnology Inc's beta into context you can compare it against those of similar companies.
Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.